{"entity":{"id":"nct06225843","kind":"trial","name":"Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis","aka":[],"tldr":"A phase 2 trial of FOLFOX in colorectal cancer, run by Alethia Biotherapeutics, now recruiting.","summary":"Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis is a phase 2 interventional study registered as NCT06225843 by Alethia Biotherapeutics, with 17 participants planned, started 2024-02-15 and due to reach its primary completion in 2026-03. Interventions recorded: Sotevtamab, FOLFOX. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06225843","url":"https://clinicaltrials.gov/study/NCT06225843"}],"tags":["ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["folfox"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06225843","phase":"2","setting":"A Proof-of-Concept Phase II Trial to Evaluate the EMT Inhibitor Sotevtamab Combined With FOLFOX Administered as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis","sponsor":"Alethia Biotherapeutics","enrolled":17,"outcomes":[]},"route":"/trials/nct06225843/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"drug":[{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/"},{"id":"sotevtamab","kind":"drug","name":"Sotevtamab","route":"/drugs/sotevtamab/"}]}}